Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Recce Pharmaceuticals Ltd has secured a significant AUD $6.75 million R&D Tax Incentive rebate from the Australian Taxation Office, bolstering its financial position to pursue innovative anti-infective treatments globally. This substantial funding underscores the Australian government’s support for pioneering life sciences and strengthens Recce’s efforts to tackle antibiotic-resistant superbugs and emerging viral pathogens. With this rebate, Recce is poised to advance its cutting-edge research and development initiatives, potentially revolutionizing infection treatments worldwide.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
